期刊
RSC ADVANCES
卷 5, 期 52, 页码 41393-41400出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/c5ra03705k
关键词
-
资金
- Natural Science Foundation of China [31271071, 81472458]
- Natural Science Foundation of Fujian Province of China [2013 J01384]
- Fujian Province medical innovation project [2014-CXB-350]
A compound with a dual role has the potential to integrate its dual functions into a single nanoscale drug delivery system. Here, based on the methotrexate (MTX)-based PEGylated chitosan (CS) nanoparticles, we validated this dual role in vivo and explored the in vivo efficiency of MTX as an early-phase tumor-targeting ligand and also as a late-phase anticancer drug. Following intravenous administration, compared with the (FA + PEG)-CS-NPs and PEG-CS-NPs, the (MTX + PEG)-CS-NPs exhibited a slower blood clearance profile, longer systemic circulation time, and significantly greater tumor accumulation. Furthermore, with the aide of folate (FA) receptor-mediated endocytosis (ability to turn cellular uptake off in normal cells, whereas it is on in cancer cells) and pH/intracellular protease-mediated hydrolyzing peptide bonds (able to turn drug release off in systemic circulation whereas it is on inside endo/lysosomes), the (MTX + PEG)-CS-NPs showed remarkably superior therapeutic efficiency compared to the commercially available MTX. More importantly, this work would stimulate interest in the use of the clinically useful MTX as a synergistically self-targeted therapeutic agent in the design of a highly convergent, flexible and simplified nanoscale drug delivery system for simultaneously targeting and treating FA receptor-overexpressing tumors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据